faq
General Questions
QCIGISH is a molecular diagnostic platform that detects Loss of Imprinting (LOI), a key biomarker for early-stage cancer detection.
By targeting LOI expression at the cellular level, QCIGISH provides a reliable visual signal of malignancy before the tumor appears physically abnormal.
Technical Questions
QCIGISH uses specifically designed probes binding to the nascent RNA at the gene expression sites to generate visual signals. Nuclei with two or more such signals are identified as having LOI.
Product-Specific Questions
Each QCIGISH test is applicable to one type of Cancer. That said, our QCIGISH methodology has been explored in over 10,000 case studies, finding our approach applicable in 13 cancer types so far in preliminary research. Suggesting massive potential for scalability.